AbCellera Biologics Inc. ABCL Canada — Long-term assets
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetsDesignatedToClosedBlockOtherLongTermInvestments.
The source filing: AbCellera Biologics Inc.’s 10-K, filed February 24, 2026.
- Filed
- Feb 24, 2026, 4:38 PM EST
- Fiscal year
- FY2025
- Accession
- 0001703057-26-000012
Of the Company’s long-term assets at December 31, 2024, $505.1 million were located in Canada, $85.7 million in the U.S., and $18.4 million in other countries. Of the Company’s long-term assets at December 31, 2025, $532.1 million were located in Canada, $81.0 million in the U.S., and $15.6 million in other countries. In 2025, the Company's additions to property and equipment, contributions to joint ventures, and research and development expenses incurred in Canada were $36.6 million, $9.0 million, and $164.0 million, respectively, and nil, nil, and $22.8 million in foreign countries.
Item 16. Form 10-K Summary
FAQ
- What is AbCellera Biologics Inc.'s canada — long-term assets?
- AbCellera Biologics Inc. (ABCL) reported canada — long-term assets of $81M in Q4 2025.
- How has AbCellera Biologics Inc.'s canada — long-term assets changed year-over-year?
- AbCellera Biologics Inc.'s canada — long-term assets decreased by 84.0% year-over-year, from $505.1M to $81M.
- What does canada — long-term assets mean?
- Represents the book value of non-current assets, such as property, plant, equipment, and intangible assets, located or utilized within the Canadian segment. This metric reflects the scale of the company's long-term physical and strategic investment in its Canadian infrastructure.
Ask your AI about AbCellera Biologics Inc.'s canada — long-term assets.
Connect your AI assistant and compare it to peers, right in your chat.
